[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"body-weight\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:body-weight":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,52,93,121,164,213,256,289,315,356,384,416,450,483,518,549],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100642828","phase-2-a-study-of-pf-08653945-and-pf-08653944-in-adults-with-overweight-or-obesity-solis-1-100642828",false,"NCT07575932","A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)","A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)","SOLIS-1","Inclusion Criteria:\n\nEligible participants for this study include:\n\n* adults aged 18 years or older with\n* obesity (BMI of 30.0 kg\u002Fm2 to 50.0 kg\u002Fm2) or with\n* overweight (BMI of 27.0 kg\u002Fm2 to \\\u003C30.0 kg\u002Fm2) who also have at least 1 prespecified weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea), at the screening visit.\n\nExclusion Criteria:\n\nParticipants who are not eligible include those with diabetes mellitus, a body weight change of \\>5% or use of weight loss medications in the 12 weeks prior to screening, a history of or plan for surgical treatment for obesity, and those who are unable or unwilling to comply with contraceptive requirements or are pregnant or lactating.","ALL","18 Years",{"count":20,"type":21},872,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).",[27,28,29,30,31,32,33,34],"Overweight","Obesity","Overweight and\u002For Obesity","Overweight or Obesity","Overnutrition","Nutrition Disorders","Nutritional and Metabolic Diseases","Body Weight",[31,32,33,34,28,27,36,37,38],"GLP-1RA","Amylin","DACRA","RECRUITING","2026-06-09",{"date":42,"type":43},"2026-06-10","ACTUAL",{"date":45,"type":43},"2026-05-11",{"date":47,"type":21},"2028-01-05",{"name":49,"class":50},"Pfizer","INDUSTRY",48,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":73,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":92},"100511439","impact-of-bright-light-therapy-on-prader-willi-syndrome-100511439","NCT05939453","Impact of Bright Light Therapy on Prader-Willi Syndrome","A Randomized, Double-Blind, Controlled Trial of Bright Light Therapy on All-Cause Excessive Daytime Sleepiness in Prader-Willi Syndrome","PWS-LT","Inclusion Criteria:\n\n* Diagnosis of PWS confirmed by genetic testing\n* Score of 12 or above on the Epworth Sleepiness Scale (ESS).\n\nExclusion Criteria:\n\n* Subjects with an eye condition that could be negatively affected by bright light such as patients with a history of retinal damage or patients needing photosensitizing medications\n* A history of previous treatment with LT\n* Patients presenting with active psychosis or mania","6 Years","88 Years",{"count":63,"type":21},50,[65],"NA","This is a placebo controlled clinical trial to assess the utility of light therapy as a sufficient treatment for excessive daytime sleepiness in patients with Prader-Willi Syndrome",[68,69,70,34,71,72],"Prader-Willi Syndrome","Excessive Daytime Sleepiness","Hyperphagia","Mood","Behavior",[74,75,76,77,78,79,80,81],"Light Therapy","Aberrant Behavior Checklist","Clinical Global Impression- Improvement","Fitbit","Actigraphy reports","Epworth Sleepiness Scale","Hyperphagia Questionnaire (HQCT)","Modified Overt Aggression Scale (MOAS)","2026-05-13",{"date":84,"type":43},"2026-05-15",{"date":86,"type":43},"2023-10-01",{"date":88,"type":21},"2026-12",{"name":90,"class":91},"Maimonides Medical Center","OTHER",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":99,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":92},"100529081","pilot-study-of-isocaloric-time-restricted-eating-on-ketone-metabolism-and-immunoregulation-100529081","NCT06169137","Pilot Study of Isocaloric Time Restricted Eating on Ketone Metabolism and Immunoregulation","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study\n2. Women between ages 18-50 years who are premenopausal (defined as regular menses and\u002For FSH \\\u003CULN)\n3. BMI of 18-24.9 or \\>=30 kg\u002Fm\\^2\n4. In good general health as evidenced by medical history and\u002For screening laboratory evaluation.\n5. Agreement to adhere to Lifestyle Considerations throughout study duration\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Diagnosis\u002Ftreatment for immune\u002Finflammatory disorder or other metabolic conditions that would interfere with study parameters, including diabetes, chronic kidney, chronic liver disease, history of hypoglycemia, and thyroid disease (with the exception of chronic controlled hypothyroidism as measured by TSH within normal limits)\n2. Current use of antihyperglycemic medications, systemic steroids, adrenergic-stimulating agents, or medications affecting sleep, circadian rhythms, or metabolism which affect parameters under investigation (examples include oral contraceptives, anti-diabetic agents, nicotinamide riboside, tryptophan, vitamin B3 supplements)\n3. Caffeine consumption in excess of approximately 300 mg (approximately three 8-oz cups of coffee) daily\n4. Factors that affect circadian rhythms including individuals who perform overnight shift work, report irregular sleep and\u002For eating schedules, and who regularly fast for more than 15 hours\u002Fday\n5. History of an eating disorder by self-report or medical history\n6. Food allergies\u002Fintolerances or dietary patterns that would prohibit consumption of metabolic diet\n7. Inability to provide informed consent\n8. Pregnancy or lactation\n9. Unstable weight with more than 5% body weight change in last previous 3 months\n10. Engaged in competitive sports training and\u002F or unwilling to comply with exercise regimen in this protocol.\n11. Consumption of more than 3 servings of alcohol daily\n12. Current smoker or regular tobacco use, vaping, or other forms of nicotine within prior 3 months\n\nThis study will recruit only women. The study design was informed by our Protocol NCT04728165 which investigates an identical 6:18h TRE intervention in males who are healthy and those with psoriasis. Based on our pilot data in men, the current study is needed to test our hypothesis in women. This study in women is a critical next step to replicate the findings in women and to understand sex-specific differences in TRE response and ketone metabolism.","FEMALE","50 Years",{"count":102,"type":21},150,[65],"Background:\n\nTime restricted eating (TRE) is a form of fasting in which a person eats only during a set window of time, which is usually between 4 and 10 hours each day. Researchers want to know more about how TRE may affect health.\n\nObjective:\n\nTo learn how TRE affects women with different body sizes.\n\nEligibility:\n\nHealthy women aged 18 to 50 years.\n\nDesign:\n\nParticipants will have 2 visits: 1 screening visit and one 5-day stay in the clinic.\n\nParticipants will fast before both visits. They will have a physical exam with blood tests. They will talk to a nutritionist about the foods they eat. They will lay under a clear hood for up to 45 minutes during a test that measures how many calories they burn while resting.\n\nParticipants will keep a food diary for up to 7 days before their clinic stay. They will apply a continuous glucose monitor the day before they go to the clinic. This is a device that attaches to the skin of the stomach. They will wear this device throughout their clinic stay.\n\nAll meals will be provided during the clinic stay. Participants will follow TRE on 3 days. They will answer survey questions and have tests during their stay, including:\n\n* DXA (dual energy X-ray absorptiometry) scan. Participants will lie on a padded table. Their body will be scanned to measure how much muscle, bone, fat, and other tissues they have.\n* Stable isotope tracer study. Small amounts of sugar and other substances will be given through a tube attached to a needle inserted into a vein in the arm. Blood samples will be collected.",[28,34],[107,108,109,110],"Diet","Time Restricted Eating","Inflammation","Ketone Bodies","2026-05-09",{"date":113,"type":43},"2026-05-12",{"date":115,"type":43},"2024-09-04",{"date":117,"type":21},"2027-02-05",{"name":119,"class":120},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":133,"conditions":134,"keywords":139,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":92},"100640329","glp-1-medication--behavioral-health-programs-on-weight--metabolic-outcomes-flourish-and-thrive-prospective-cohort-study-100640329","NCT07588984","GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study","GLP-1 Medication & Behavioral Health on Weight and Metabolic Outcomes: FLOURISH (Functional Longitudinal Outcomes Under Intentional Small Habits) & THRIVE (Trajectories of Health, Resilience & Integrated Vitality Evaluation) Cohort Study","FLOURISH","Inclusion Criteria:\n\n* Speaks English\n* Community-dwelling, community-living status\n* Able to ambulate independently, with or without aids or devices\n* Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities\n* Provides informed consent for study participation\n* Commitment and willingness to participate, as assessed by completion of decisional balance exercise\n* Program-specific eligibility:\n* Medication arms only: Meets standard of care program enrollment criteria for GLP-1 medication. Did not add other products or programs to Noom subscription.\n* Noom Weight only: Individual who is not interested in medication\n* Education-only Control Group: Individual who is interested in weight loss who is not currently enrolled in a structured weight loss program or medication program and does not intend to for the duration of the study Free Tier only: Willingness to use Free Tier\n\nExclusion Criteria:\n\n* Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)\n* GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)\n* Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program\n* Previous or planned (during the 12-month study) bariatric surgery\n* Active eating disorder\n* Active cancer\n* Type 1 diabetes or current Insulin use\n* Currently taking a medication known to cause weight gain (e.g., antipsychotics, antidepressants, diabetes medication, or corticosteroids)\n* Depression screen results in a PHQ-8 score of 20 or greater.\n\nAll medicated arms and Noom Weight arms (only):\n\n\\- Purchased more than the base Noom program offered for participant's specific arm\n\nGLP-1 Medication Arms Only:\n\n* GLP-1 agonist use is contraindicated (per program criteria) in members with:\n* Personal or family history of medullary thyroid cancer\n* Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)\n* Personal history of Pancreatitis","64 Years",{"count":131,"type":21},2310,"OBSERVATIONAL","This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement.\n\nFLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose).\n\nTHRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control.\n\nParticipants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.",[135,136,137,34,138],"Obesity & Overweight","Weight Loss","Preventative Health","Cardiovascular Disease Risk Factor",[140,141,142,143,144,145,146,147,148,149,150,151,152,153,154],"GLP-1","Microdose","weight","body composition","metabolic","biomarkers","longevity","glucagon-like peptide-1","semaglutide","tirzepatide","microdosing","digital health","weight loss","behavioral health","real world evidence","NOT_YET_RECRUITING","2026-05-08",{"date":84,"type":43},{"date":159,"type":21},"2026-04-30",{"date":161,"type":21},"2029-05",{"name":163,"class":50},"Noom Inc.",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":171,"sex":99,"minAge":172,"maxAge":129,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":92},"100385016","metabolic-and-bio-behavioral-effects-of-following-recommendations-in-the-dietary-guidelines-for-americans-100385016","NCT04293224","Metabolic and Bio-behavioral Effects of Following Recommendations in the Dietary Guidelines for Americans","DGA4ME","Inclusion Criteria:\n\n* Body Mass Index (BMI) 23-39.9 kg\u002Fm2 or 32-50% body fat percentage\n* Willingness to have blood drawn\n* The criteria listed above and at least one of the following: Fasting glucose ≥100 mg\u002FdL but \\\u003C126 mg\u002FdL or Fasting triglyceride ≥125 mg\u002FdL or HDL-cholesterol ≤50 mg\u002FdL or Blood Pressure (BP): Systolic BP ≥130 mmHg or Diastolic BP ≥85 mmHg or Hemoglobin A1C ≥ 5.7 and \\\u003C6.5%\n\nExclusion Criteria:\n\n* Active participation in another research study\n* Tested positive for COVID-19 within the past 10 days\n* Been in close contact with a COVID-19 positive person within the past 14 days\n* Blood Pressure (BP): Systolic BP ≥140 mmHg or Diastolic BP ≥90 mmHg\n* LDL cholesterol ≥190 mg\u002FdL\n* Triglycerides ≥500 mg\u002FdL\n* Current use of smoking or chewing tobacco, e-cigarettes, cigars, vaping, cannabis or other use of nicotine containing products (within the past 6 months)\n* Current use of dietary supplements and\u002For unwillingness to cease intake of dietary supplements\n* Vegan or vegetarian lifestyle or any other dietary restrictions that would interfere with consuming the intervention foods and beverages (including dietary intolerances, allergies and sensitivities)\n* Unwillingness to consume intervention foods and beverages\n* Engage in more than moderate drinking (\\> 1 drink serving per day) or binge drinking (4 drinks within two hours).\n* Unwillingness to cease alcohol intake as required for specific duration of the study\n* Excessive intake of caffeine containing products (excessive defined as ≥ 400 mg\u002Fday)\n* Unwillingness to refrain from caffeine intake on lab visit days.\n* Intentional weight change of ≥5% of body weight within 6 months of entry into the study\n* Diagnosis of disordered eating or eating disorder\n* Recent diagnosis of any of the following or measurement on screening lab tests: Anemia (hemoglobin \\\u003C11.7 g\u002FdL) or abnormal liver or thyroid function (defined as liver enzymes that are \\>200% of upper limit (ALT upper limit is 43 U\u002FL or Aspartate transaminase (AST) upper limit is 54 U\u002FL) and thyroid function tests: Thyroxine (T4, free) \\\u003C0.56 or \\>1.64 ng\u002FdL; Thyroid-stimulating hormone (TSH) \\\u003C0.35 or \\>5.6 μIU\u002FmL).\n* History of any of the following: Gastric bypass surgery, inflammatory bowel disease (IBD) or other GI conditions that would interfere with consuming the intervention foods, active cancer in the past three years excluding squamous or basal cell carcinomas of the skin that have been handled medically by local excision and other serious medical conditions\n* Recent dental work or have conditions of the oral cavity that would interfere with consuming the intervention foods and beverages\n* Taking any medication in the class of antipsychotics\n* Long term use of antibiotics\n* Taking any over the counter or prescribed medication for any of the following: Elevated lipids, elevated glucose, high blood pressure, weight loss or conditions that require corticosteroids (e.g. asthma, arthritis or eczema).\n* Are pregnant, planning to become pregnant within the duration of the study or breastfeeding.",true,"19 Years",{"count":174,"type":21},70,[65],"This study, at the Western Human Nutrition Research Center (WHNRC), will focus on whether or not achieving and maintaining a healthy body weight is the most important health promoting recommendation of the Dietary Guidelines for Americans (DGA).The investigators hypothesize that improvement in cardiometabolic risk factors resulting from eating a DGA style diet will be greater in people whose energy intake is restricted to result in weight loss compared to those who maintain their weight. The investigators further propose that during a state of energy restriction, a higher nutrient quality diet such as the DGA style diet pattern, will result in greater improvement in cardiometabolic risk factors compared to a typical American diet (TAD) pattern that tends to be lower nutrient quality (more energy-dense and less nutrient-rich.)",[28,34],[179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203],"Dietary Guidelines for Americans","Physical Activity for Americans","Mediterranean Diet","Controlled Feeding","Women","PreDiabetes","Metabolic Syndrome","Cognitive Function","Stress, Physiological","Executive Function","Cardiovascular Diseases","Cardiovascular Risk Factor","Eating Behavior","Glucose Intolerance","Metabolomic Profiling","Metabolic flexibility","Gut Microbiome","Genome Testing","Prehypertension","Insulin Resistance","Insulin Sensitivity","Hypertriglyceridemic","Waist to Hip Ratio","Allostatic Load","Physiology","2026-04-24",{"date":159,"type":43},{"date":207,"type":43},"2022-08-01",{"date":209,"type":21},"2026-09-30",{"name":211,"class":212},"USDA, Western Human Nutrition Research Center","FED",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":171,"sex":99,"minAge":172,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":223,"conditions":224,"keywords":237,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":255},"100628121","breastmilk-and-the-link-to-overweightobesity-and-maternal-diet-in-the-mother-breastmilk-child-triad-100628121","NCT07457515","Breastmilk and the Link to Overweight\u002FObesity and Maternal Diet in the Mother-breastmilk-child Triad","Analysis of the Transmission of Overweight\u002FObesity in the Mother-breastmilk-child Triad in Relation to Maternal Cardiometabolic Status and Diet","BLOOM-Triad","Inclusion Criteria:\n\nfor mother:\n\n* at least 19 years,\n* plan of exclusively or predominantly breastfeeding for 6 months,\n* consent to a sampling of biological material and participate in all planned procedures (for both mother and infant),\n* willingness to finish the follow-up,\n* well-understanding of the Polish language (for non-Polish nationalities); for infants:\n* 1 month or less,\n* clinically healthy,\n* none or one formula feeding per day\n\nExclusion Criteria:\n\nfor mother:\n\n* type 1 or 2 diabetes diagnosed before pregnancy,\n* uncontrolled thyroid disease,\n* breastfeeding more than 1 child or being a milk donor,\n* tobacco\u002Falcohol use during pregnancy or currently,\n* inability to express a sufficient amount of milk; for infants:\n* congenital disease,\n* birth from a multiple pregnancy,\n* preterm birth (\\\u003C37 Hbd).",{"count":222,"type":21},165,"The prospective 5-month follow-up study will involve 150 mother-infant dyads grouped based on maternal baseline BMI category (normal weight, overweight, obesity). The investigators plan 3 study visits (1, 3, and 6 months postpartum) with analysis the following parameters and outcomes:\n\n1. maternal anthropometry and body composition;\n2. maternal dietary intake and dietary patterns (with results of biomarker-based validation);\n3. maternal status of lipophilic antioxidants, selected vitamins, and fatty acids profile that may be related to adipose tissue metabolism, inflammation, and cardiometabolic status;\n4. maternal metabolomics, adipokines, insulin, selected biomarkers of inflammation, altered glucose metabolism, and oxidation;\n5. breastmilk composition assessed by systemic approach (macronutrients, fatty acids profile, lipophilic antioxidants, adipokines, hormones, immunological profile, and preliminary lipidomic analysis in part of the study group);\n6. infant growth trajectory, body composition, urine metabolomics, and biomarkers of oxidative stress.\n\nAdditionally, maternal and infant stool, buccal swabs, and human milk samples will be banked for further microbiome analysis studies.",[34,135,225,226,227,228,229,230,231,232,233,234,235,236],"Human Milk\u002FBreastfeeding","Body Composition","Maternal Cardiometabolic Health","Growth & Development","Metabolomic Profile","Infant Body Composition and Metabolism","Carotenoid Status","Fatty Acid Status","Immunologic Markers","Adipokines","Inflammation Biomarkers","Vitamin E",[238,239,240,107,234,241,242,243,109,244,27,28,245],"Lactation","Body composition","Infant development","Carotenoids","Fatty acids","Metabolomics","Oxidative stress","Tocopherols","2026-03-02",{"date":248,"type":43},"2026-03-09",{"date":250,"type":21},"2026-02",{"date":252,"type":21},"2029-09",{"name":254,"class":91},"Warsaw University of Life Sciences",4,{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":171,"sex":17,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":269,"conditions":270,"keywords":277,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":287,"locationsCount":92},"100616529","the-effect-of-piomi-and-chronobiological-nutrition-on-readiness-for-feeding-full-transition-to-oral-feeding-and-body-weight-100616529","NCT07306793","The Effect of PIOMI and Chronobiological Nutrition on Readiness for Feeding, Full Transition to Oral Feeding and Body Weight","The Effect of Oral Motor Intervention and Chronobiological Approach to Feeding Models Applied to Preterm Infants on Infants' Readiness to Feed, Transition to Total Oral Feeding, and Body Weight","PIOMI","Inclusion Criteria:\n\n* Preterm infants with a postnatal age of 29-33 weeks,\n* Whose vital signs and clinical condition have been stable for at least 24 hours,\n* Whose APGAR score at 1 and 5 minutes (Activity-Pulse-Grimace-Appearance-Respiration) is 4 or higher.\n\nExclusion Criteria:\n\n* Infants with major congenital anomalies (such as congenital heart disease, cleft palate, cleft lip) or birth trauma,\n* Infants with RDS,\n* Infants diagnosed with asphyxia,\n* Infants with intraventricular hemorrhage,\n* Infants with Neonatal Withdrawal Syndrome,\n* Infants with Fetal Alcohol Syndrome,\n* Infants included in the study group who develop any complications or whose stable condition deteriorates during the follow-up period,\n* Infants with feeding intolerance or who are interrupted from feeding for more than 48 hours,\n* Infants who develop sepsis,\n* Infants who develop necrotizing enterocolitis,\n* Infants receiving mechanical ventilation support,\n* Infants who receive narcotic analgesia or sedation,","29 Weeks","33 Weeks",{"count":267,"type":21},54,[65],"This is a randomized controlled experimental study evaluating the effects of oral motor intervention and chronobiological approach to feeding model applied to preterm infants on feeding readiness, transition to total oral feeding and body weight.",[271,272,273,34,274,275,276],"Neonatal İntensive Care","Nutrition With A Chronobiological Approach","Readiness For Feding","Breast Milk","Nutrition","Premature Birth",[271,272,273,34,278,279,280],"Transitioning To Total Oral Feeding","Premature Infant Oral Motor Intervention (PIOMI)","Prematüre","2026-01-01",{"date":283,"type":43},"2026-01-06",{"date":285,"type":43},"2025-03-01",{"date":209,"type":21},{"name":288,"class":91},"Aydin Adnan Menderes University",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":171,"sex":17,"minAge":296,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":92},"100498776","lipo-teen-the-lifestyle-in-pregnancy-and-offspring-teenagers-100498776","NCT05774652","LiPO Teen (the Lifestyle in Pregnancy and Offspring Teenagers","LiPO Teen (the Lifestyle in Pregnancy and Offspring Teenagers): Identification of Modifiable Risk Factors for Childhood Obesity - a Follow-up of a Randomized Controlled Trial","Inclusion Criteria:\n\n* Mothers in the initial LiP study selected at the baseline study in 2007-2010\n* Teenagers of mothers in the initial LiP study\n\nExclusion Criteria:\n\n• None","13 Years","65 Years",{"count":299,"type":21},301,[65],"The study is a follow-up of a Randomized Controlled Trial (RCT) performed in 2007-10 - the \"Lifestyle in Pregnancy\" LiP study.\n\nThe LiP study included 360 pregnant women with BMI ≥30 kg\u002Fm2 from Odense University Hospital and Aarhus University Hospital. The women were randomized to intervention with low-calorie diet and physical activity from gestational age 10-14 in pregnancy and until delivery - or to a standard care control group. The objective of the LiPO-Teen project is to perform a clinical follow-up study of the eligible 301 mothers who completed the trial until delivery with a liveborn child, and their 14 year-old offspring. The overall ambition is to understand whether lifestyle intervention in pregnancy prevents obesity and its complications across generations, with a specific focus on modifiable factors.",[28,303,304,305,34],"Life Style, Healthy","Follow-up","Gestational Weight Gain","2025-11-16",{"date":308,"type":43},"2025-11-19",{"date":310,"type":43},"2023-10-26",{"date":312,"type":21},"2026-03-01",{"name":314,"class":91},"Odense University Hospital",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":17,"minAge":296,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":326,"briefSummary":327,"conditions":328,"keywords":336,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":92},"100582507","addressing-weight-bias-internalization-to-improve-adolescent-weight-management-outcomes-randomized-pilot-trial-100582507","NCT06864208","Addressing Weight Bias Internalization to Improve Adolescent Weight Management Outcomes: Randomized Pilot Trial","Piloting an Intervention to Address Weight Bias Internalization to Improve Adolescent Weight Management Outcomes","SWIFT","Inclusion Criteria:\n\n* Speak English;\n* 13-17 years of age;\n* BMI at or above \\>95th%ile for age and sex;\n* Have at least one caregiver available to provide consent and participate in sessions;\n* Agree to study participation;\n\nExclusion Criteria:\n\n* Cognitive impairment or developmental delay impairing participation in a group setting;\n* Current participation in a weight management program or recent weight loss of 5% of body weight or more;\n* Medical condition known to impact weight or that would otherwise prevent participation;\n* Current use of glucagon-like peptide-1 (GLP-1) receptor agonists;","17 Years",{"count":325,"type":21},64,[65],"Weight stigma and weight bias internalization (WBI) are common among adolescents at higher weight statuses. WBI is associated with negative physical and mental health outcomes. The current study aims to test an intervention for weight stigma and WBI combined with an evidence-based adolescent weight management program. Eligible adolescents (13-17) will be assigned by chance to one of two groups: 1) a 4-week intervention focused on weight stigma and WBI followed by a 16-week behavioral weight management program; or 2) a 4-week health information control (to include non-weight-related health promotion topics such as smoking and skin cancer prevention) followed by the same 16-week weight management program but without the WBI and weight stigma content. Study outcomes will be assessed at the 4-week and post-treatment (20 week) timepoints.",[329,34,330,331,332,333,334,335],"Weight","Weight Bias","Weight Stigma","Physiological Stress","Biological Markers of Stress","Biological Markers of Inflammation","Eating Behaviors",[337,338,329,339,340,341,342,343,344,345,346],"Adolescents","Teens","C-reactive protein","CRP","Interleukin-6","IL-6","Eating behaviors","Behavioral weight management","Weight bias","Weight stigma","2025-09-22",{"date":349,"type":43},"2025-09-24",{"date":351,"type":43},"2025-03-25",{"date":353,"type":21},"2027-02",{"name":355,"class":91},"The Miriam Hospital",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":171,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":366,"conditions":367,"keywords":370,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":92},"100600990","sports-nutrition-assessment-program-100600990","NCT07104669","Sports Nutrition Assessment Program","Sports Nutrition Assessment Program at the University of Alicante","NutriEvalUA","Inclusion Criteria:\n\n* Acceptation of informed consent\n\nExclusion Criteria:\n\n* No attendance to the evaluations\n* Reporting less than 80% of assistance to physical activity sessions reported by trainer",{"count":365,"type":21},100,"The NutriEvalUA program is an observational study aiming to assess the nutritional status, body composition, hydration, physical activity, and health indicators in university athletes. The main objective is to describe and evaluate dietary habits, supplement use, physical condition, and related risk factors to improve health and sports performance in this population. The main question it aims to answer is: What is the nutritional, body composition, hydration, physical activity, and general health profile of university athletes at the University of Alicante, and which factors are associated with potential risks to their performance and well-being?",[368,34,369],"Diet Habit","Athlete Foot",[371,372,373,374],"sport nutrition","dietary-nutritional assessment","athletes","questionnaires","2025-07-29",{"date":377,"type":43},"2025-08-05",{"date":379,"type":21},"2025-10-01",{"date":381,"type":21},"2031-06-30",{"name":383,"class":91},"University of Alicante",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":171,"sex":17,"minAge":391,"maxAge":297,"enrollmentInfo":392,"targetDuration":4,"studyType":22,"phases":394,"briefSummary":395,"conditions":396,"keywords":400,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":92},"100280677","bariatric-embolization-of-arteries-for-the-treatment-of-nonalcoholic-steatohepatitis-100280677","NCT02933554","Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis","A Single Center, Non-randomized Study to Evaluate the Safety and Efficacy of Left Gastric Artery Embolization, to Promote Short-term Weight Loss in Obese Patients With Nonalcoholic Steatohepatitis (NASH) and Thereby Improve NASH","Inclusion Criteria:\n\n1. Male or Female, aged 22 years or older.\n2. Willing, able and mentally competent to provide written informed consent and willing to comply with all study procedures and be available for the duration of the study\n3. BMI \\>35 kg\u002Fm2\n4. Adequate hematological, hepatic and renal function as follows:\n\n   1. Hematological: Hematological: If the bariatric embolization procedure is being performed by femoral access: platelets \\> 50 x 109\u002FL, INR \\\u003C1.5. If the bariatric embolization procedure is being performed by radial access: platelets \\>35 x 109\u002FL and INR \\\u003C1.5 OR platelets \\>50 x 109\u002FL and INR between 1.5 and 2.\"\n   2. Hepatic : Total bilirubin \\\u003C3 mg\u002FdL\n   3. Renal: Estimated GFR \\> 60ml\u002Fmin.1.73m2\n5. If Center for Epidemiological Studies Depression (CESD) score \\> or =16 AND is in care of behavior health specialist who has indicated patient has adequate coping mechanisms to undergo procedure and does not foresee mental health as barrier to participation in study.\n6. Elevated alanine or aspartate aminotransferase values (ALT \\>41 or AST\\>34 U\u002FL).\n7. Liver biopsy showing evidence of NASH in the past 12 months.\n8. No evidence of another form of liver disease.\n9. Patients diagnosed with NASH and have evidence of failing other methods of weight loss through diet, exercise and behavior modification.\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Active substance abuse\n3. Significant psychiatric problems, severe enough to cause suffering or a poor ability to function in life. Center for Epidemiological Studies Depression (CESD) score \\> or = 16 without psychiatric evaluation. \\[If Center for Epidemiological Studies Depression (CESD) score \\> or =16 AND is in care of behavior health specialist who has indicated patient has adequate coping mechanisms to undergo procedure and does not foresee mental health as barrier to participation in study.\\]\n4. Significant alcohol consumption ( \\>20 g\u002Fday in women, \\>30 g\u002Fday in men)\n5. Weight \\> 400 lbs, BMI \\> 50 kg\u002Fm2.\n6. Contraindications to obtaining a liver biopsy\n7. Subjects with pre-existing abdominal pain will be excluded (because of the potential confusion with pain related to the procedure).\n8. Subjects who are intolerant to PPIs\n9. Subjects requiring any anticoagulant medications should be excluded if radial access cannot be obtained.\n10. Subjects with platelets \\\u003C35 x 109\u002FL and INR \\> 2.0\n11. Subjects who are taking aspirin\u002F NSAIDs and in whom these medications are unable to be withdrawn from aspirin and NSAIDs for at least 3 days prior to the LGAE procedure and for 30 days following the LGAE procedure (because of the potential risks of gastric bleeding following the procedure).\n12. Presence of systemic illness or other medical conditions relevant to survival .(Note that in the HCC pre liver transplant cohort, the presence of HCC will not be considered an exclusion criteria)\n13. Metastatic cancer\n14. Evidence of decompensated liver disease (uncontrolled ascites, or uncontrolled spontaneous encephalopathy)\n15. prior surgical weight loss procedures including gastroplasty, jejunoileal, or jejunocolic bypass, total parenteral nutrition within the past 6 months; Prior history of gastric pancreatic, hepatic, and\u002For splenic surgery\n16. Prior embolization to the stomach, spleen or liver, unless the prior embolization was a transarterial chemoembolization (TACE) to the liver for HCC.\n17. If review of available prior imaging studies (i.e CT, MRI, or US)shows potential anatomical variations, presence of severe atheromatous disease, large arteriovenous shunting of blood.\n18. Abnormal Endoscopy - large sliding hiatal hernia or paraesophageal hernia, active peptic ulcer disease, active H. pylori infection\n19. History of abnormal Nuclear Gastric Motility examination-defined as delayed emptying of gastric contents \\> 90%, 60% and 10% at 1 hour, 2 hours, and 4 hours respectively.\n20. ASA Class 4 or 5\n21. Child Pugh classification C\n22. Known aortic disease, such as dissection or aneurysm; peripheral arterial disease or other cardiovascular disease.\n23. Type 2 diabetes on anti-diabetic medications that are known to cause hypoglycemia. e.g. sulphonylureas, meglitinides\n24. Patients with a known other cause for their increased liver enzyme levels such as viral hepatitis (B or C), autoimmune\u002Fchronic immune hepatitis, primary biliary cholangitis, metabolic and genetic hemochromatosis, Wilson's disease, or alpha-1 antitrypsin deficiency\n25. Patient taking hepatotoxic drugs. List of drugs causing steatohepatitis include but are not limited to: amiodarone, chemotherapy (5-fluorouracil, tamoxifen, irinotecan, cisplatin, and asparaginase), glucocorticoids, methotrexate, sulfonamides, antithyroid drugs, phenytoin, tetracyclines, isoniazid, salicylates, and valproic acid.\n26. Contraindications to obtaining a liver biopsy (NASH cohort)\n27. Patients taking other trial medications for NASH.","22 Years",{"count":393,"type":21},8,[65],"Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of progression of fibrosis in NASH is crucial, as they are at a high risk for cirrhosis and may need liver transplant.\n\nRecent studies have shown that blocking blood vessels to a particular portion of the stomach (bariatric or left gastric artery embolization) can temporarily decrease levels of the appetite inducing hormone ghrelin, and result in weight loss.The purpose of this study is to determine if Left gastric artery embolization (LGAE) in patients with obesity and NASH leads to clinically significant weight loss with improvement of NASH.",[28,136,34,397,398,399],"Nonalcoholic Steatohepatitis","Nonalcoholic Fatty Liver Disease","NAFLD",[401,402,403,404,405,406],"bariatric surgery","minimally invasive","Embolization","NASH","ghrelin","gastric artery embolization","2025-07-23",{"date":409,"type":43},"2025-07-28",{"date":411,"type":21},"2025-12",{"date":413,"type":21},"2027-06",{"name":415,"class":91},"Keith Pereira, MD:",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":171,"sex":424,"minAge":425,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":429,"conditions":430,"keywords":433,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":92},"100535522","diet-induced-changes-in-genetic-material-100535522","NCT06252922","Diet-Induced Changes in GEnetic Material","A Pilot Study to Examine Metabolic Flexibility as a Mechanism for Diet- Induced Epigenetic Alterations in Male Gametes","DIG 'EM","Inclusion Criteria:\n\n* Male based on biological sex\n* Age 20-35 years\n* BMI between 18.5 and 24.9 kg\u002Fm2\n* White\u002FCaucasian\n* Willing to consume pre-prepared meals\n* Willing to wear an accelerometer and continuous glucose monitor (CGM)\n* Willing to track diet intake\n* Willing to stay 24 hours, including overnight in a research clinic\n* Willing to provide blood and sperm samples\n* Willing to consent to whole-genome sequencing of DNA\n\nExclusion Criteria:\n\n* Unstable weight in the last 3 months (±5% weight loss or gain)\n* Shift work or working in a factory setting\n* Habitual smoking or use of tobacco products, including vaping, within the past 6 months.\n* History of clinically diagnosed diabetes\n* Hypertension (\\>140\u002F90 mmHg measured at screening)\n* Has undergone bariatric surgery\n* History of cardiovascular disease, neurological disease, or other chronic diseases, including cancer\n* History of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)\n* Adherence to special or restrained diets (e.g., low-CHO, low-fat, or vegetarian\u002Fvegan diets) or food allergies associated with study foods.\n* Currently engaging in \\>150 minutes moderate-intensity or \\>75 minutes of vigorous-intensity physical activity each week\n* Drinking more than 14 servings of beer or alcohol per week\n* Depressive (Score ≥10), anxiety (Score ≥8), and stress (Score≥15) symptomology (Score ≥16) from the 42-item Depression, Anxiety, Stress Scales (DASS)","MALE","20 Years","35 Years",{"count":428,"type":21},10,"This is a pilot study in 10 men to test the hypothesis that perturbations in substrate flux and the circulating metabolic and pro-inflammatory milieus during a high-fat diet paradigm will modulate DNA methylation of genes in sperm associated with obesity and cardiometabolic dysfunction.",[431,34,432],"Diet, Healthy","Metabolic Disturbance",[434,435,436,437,438,439,440],"Healthy Weight","High-Fat Diet","Sperm DNA Methylation","Metabolic Flexibility","DNA Damage","Substrate Flux","Preconception","2025-05-27",{"date":443,"type":43},"2025-05-31",{"date":445,"type":43},"2023-11-11",{"date":447,"type":21},"2026-12-30",{"name":449,"class":91},"Pennington Biomedical Research Center",{"id":451,"slug":452,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":460,"conditions":461,"keywords":467,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":482},"100545898","investigating-paclitaxel-toxicity-in-breast-cancer-the-roles-of-physical-activity-and-body-composition-100545898","NCT06387901","Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.","Dose-limiting Toxicities of Paclitaxel in Breast Cancer Patients: Studying Interactions Between Pharmacokinetics, Physical Activity, and Body Composition: an Observational Pilot Study.","PABTOX","Inclusion Criteria\n\n* Female patients with a diagnosis of breast cancer: Specifically targeting those diagnosed with stage II or III breast cancer, to understand the effects of paclitaxel within a somewhat uniform disease severity group.\n* Planned for 12 cycles of Paclitaxel (PTX) in a (neo-)adjuvant setting: The study focuses on patients scheduled to undergo a standard 12-week, once-a-week paclitaxel chemotherapy regimen as part of their treatment plan.\n* Age 18 or older in (pre-)menopausal status: Adult patients of any menopausal status are eligible, ensuring a wide demographic representation.\n* Prior taxane use is allowed if treatment in the adjuvant setting finished over a year ago: This criterion allows for the inclusion of patients who may have previously undergone taxane-based treatments, provided there has been a sufficient washout period to minimize the influence of prior treatments on the study outcomes.\n\nExclusion Criteria\n\n* Cognitive impairment (unable to understand test instructions): Ensuring participants can comprehend and follow study procedures and requirements is crucial for data integrity and participant safety.\n* Participation in clinical trials of experimental drugs: To avoid confounding effects from other investigational treatments and focus on the impact of standard-of-care paclitaxel therapy.\n* Documented intolerance or allergy to PTX (non-documented intolerance or allergy will lead to drop-out): Participants must be able to tolerate paclitaxel, as adverse reactions could compromise their safety and affect study results.\n\nInteracting drugs in home medication: Patients using medications known to interact with paclitaxel could experience altered drug metabolism or increased toxicity, potentially skewing study outcomes.\n\n* Male sex: The study is focused on breast cancer in female patients, as the disease's presentation, treatment, and outcomes can vary significantly between genders.\n* Age under 18 years: Ensuring all participants are legal adults helps adhere to ethical standards and regulatory requirements concerning consent and participation in clinical research.",{"count":459,"type":21},40,"This study looks into how a common breast cancer treatment, paclitaxel, can sometimes cause severe side effects that make it hard for patients to continue treatment. These side effects can significantly affect a patient's quality of life and even impact their recovery and overall health costs. What's interesting about this research is that it considers how a patient's lifestyle, specifically their physical activity levels and body makeup (like how much muscle and fat they have), might influence these side effects.\n\nThe researchers are doing a detailed study with 40 women receiving paclitaxel treatment, tracking how the drug is processed in their bodies and how their body composition and physical activity might play a role in the side effects they experience. They are using a special method to monitor drug levels in the blood and are also keeping tabs on the patients' health and physical activity through questionnaires and modern tracking devices.\n\nThe goal here is twofold: first, to better understand why these side effects happen to some people and not others, and second, to develop a model that can predict who might be at higher risk for these side effects based on their body composition, lifestyle, and how their body handles the drug. This could lead to more personalized treatment plans that could help reduce the risk of severe side effects and improve the overall treatment experience for patients with breast cancer.\n\nIn simpler terms, this research is trying to find a way to make breast cancer treatment with paclitaxel safer and more comfortable by considering how a person's lifestyle and body type might affect their reaction to the drug. This could make a big difference in helping patients complete their treatment successfully and with a better quality of life.",[462,463,464,465,34,466],"Breast Cancer","Paclitaxel Adverse Reaction","Chemotherapeutic Toxicity","Chemotherapeutic Agent Toxicity","Physical Inactivity",[468,469,470,143,471,472],"breast cancer","chemotherapy","physical activity","muscle mass","fat mass","2024-10-29",{"date":475,"type":43},"2024-11-01",{"date":477,"type":43},"2024-07-30",{"date":479,"type":21},"2025-10-31",{"name":481,"class":91},"Universitair Ziekenhuis Brussel",2,{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":99,"minAge":491,"maxAge":18,"enrollmentInfo":492,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":505,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":92},"100558914","in-person-lifestyle-program-for-black-adolescent-girls-at-risk-for-type-2-diabetes-100558914","NCT06557317","In-Person Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes","Examining the Preliminary Efficacy of an In-Person Lifestyle Intervention for Black Female Adolescent\u002FCaregiver Dyads at Risk for Type 2 Diabetes Mellitus","BGW In-Person","Inclusion Criteria for adolescent participants:\n\n* 12-18 years of age\n* self-identify as Black or African American\n* have obesity (\\>=95th percentile BMI)\n\nExclusion Criteria for adolescent participants:\n\n* pregnant or within 3 months postpartum.\n* participated in a formal weight management program within 6 months prior to study.\n* currently taking medications or diagnosed with a condition known to influence metabolism, physical activity ability, or cognitive function.\n* have previously undergone bariatric surgery.\n* have type 2 diabetes.\n* unable to speak English or have developmental conditions that interfere with ability to communicate.\n\nInclusion Criteria for caregiver participants:\n\n* 18 years or older.\n* proficiency in speaking English.\n* live in the same household as the adolescent who will also be enrolled.\n* prepares the majority (\\>50%) of meals in the household.\n\nExclusion Criteria for caregiver participants:\n\n* pregnant or within 3 months postpartum.\n* unable to speak English or have developmental conditions that interfere with ability to communicate.","12 Years",{"count":493,"type":21},60,[65],"The aim of this study is to look at changes in diabetes-related risk factors in Black adolescent girls who are at risk for type 2 diabetes and their primary female caregiver after both participating in a 12-week in-person lifestyle program.",[497,498,499,500,501,502,503,27,31,32,34,504],"Behavior, Adolescent","Childhood Obesity","Diabetes Mellitus, Type 2","Pediatric Obesity","Glucose Metabolism Disorders","Metabolic Disease","Endocrine System Diseases","Diabetes Mellitus",[337,506,507,508,28],"In-Person Lifestyle Program","Diabetes prevention","Black girls","2024-08-14",{"date":511,"type":43},"2024-08-16",{"date":513,"type":21},"2024-08",{"date":515,"type":21},"2024-12-31",{"name":517,"class":91},"Cornell University",{"id":519,"slug":520,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":171,"sex":17,"minAge":60,"maxAge":526,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":529,"briefSummary":530,"conditions":531,"keywords":534,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":92},"100547591","a-new-technological-intervention-to-address-childhood-obesity-100547591","NCT06409962","A New Technological Intervention to Address Childhood Obesity:","A New Technological Intervention to Address Childhood Obesity: Approach to Multidimensional Intervention","NURSPEDIAOBE","Inclusion Criteria:\n\n* Students from the school\n* Pediatric from age 6 to 16\n* Students from the school that confirmed approval\n* Signed informed consent by the minor\n* Signed informed consent by the minor's parents or guardians.\n\nExclusion Criteria:\n\n* Presence of HbA1c levels below 5.7%\n* Presence of HbA1c levels above 6.4%\n* Presence of pathological metabolic diseases, such as diabetes or metabolic syndrome\n* Presence of other diseases related to intestinal integrity or skin issues.\n* Lack of the signed informed consent by the minor and legal guardian","16 Years",{"count":528,"type":21},215,[65],"Childhood obesity is a global public health issue, with rising prevalence rates. In Spain, the problem is significant, particularly in the southern regions. Factors contributing to childhood obesity include dietary habits, lack of physical activity, and socioeconomic influences.\n\nEfforts to address childhood obesity in Spain include various programs focusing on dietary modification, increased physical activity, and family involvement. Despite these initiatives, there is a need for continued intervention, as changing dietary and lifestyle patterns have led to reduced fruit and vegetable consumption and increased sedentary behavior among children.\n\nChildhood obesity has concerning health implications, including heart-related issues. Echocardiography plays a vital role in early detection.\n\nGiven the limited research on the impact of childhood obesity on musculoskeletal development and mobility, a comprehensive study is needed to analyze its prevalence and associated factors. The study aims to assess the effectiveness of nutritional interventions administered by school nurses.\n\nIn summary, childhood obesity in Spain is a growing concern, with multifaceted causes and health implications. Ongoing efforts are required to combat this issue and promote healthier lifestyles among children.",[34,532,533],"Dyslipidemias","Musculoskeletal Diseases",[535,536,537,538,539],"pediatric","body mass index","intervention","anthopometric","blood pressure","2024-06-10",{"date":542,"type":43},"2024-06-11",{"date":544,"type":43},"2024-05-30",{"date":546,"type":21},"2026-12-31",{"name":548,"class":91},"Universidad de Córdoba",{"id":550,"slug":551,"hasResults":11,"nctId":552,"briefTitle":553,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":558,"conditions":559,"keywords":562,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":92},"100352761","body-mass-index-bmi-and-quality-of-life-qol-in-cancer-patients-100352761","NCT03873064","Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients","BMI-QoL","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of solid tumor\n2. Age \\>18 years\n3. Signed informed consent\n4. Life expectancy \\> 12 weeks\n\nExclusion Criteria:\n\n1. Inability to fill out the EORTC QLQ-C30 questionnaire.\n2. Absence of a certain diagnosis of solid tumor (e.g. subjects on screening programs)\n3. Diagnosis of second malignancies that might bias results interpretation",{"count":557,"type":21},1380,"BMI is a simple and widely recorded variable that may capture obesity or cachexia in cancer patients. How BMI is associated to health-related quality of life (HR-QoL) in such patients is poorly investigated.\n\nHigh BMI may be associated to obesity, an increased burden of comorbidity, reduced physical activity and, in some settings, to more aggressive oncological disease. On the other hand, low BMI may reflect enhanced weight loss, cachectic syndrome, higher tumor burden and adverse prognostic features which all deteriorate quality of life. The aim of the present study is to evaluate the association of BMI and HR-QoL as measured by the EORTC-QLQ-C30 questionnaire in several cancer settings (such as localized vs metastatic or distinct primary tumors).",[560,34,561],"Neoplasm Malignant","Quality of Life",[563,564,565,566],"BMI","EORTC QLQ-C30","metastatic cancer","localized cancer","2024-02-01",{"date":569,"type":43},"2024-02-02",{"date":571,"type":43},"2019-01-15",{"date":573,"type":21},"2034-01-15",{"name":575,"class":91},"University of Rome Tor Vergata"]